Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pan-tumor × Capecitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 162 Colorectal Neoplasms 133 Rectal Neoplasms 106 Stomach Neoplasms 104 Neoplasm Metastasis 56 Pancreatic Neoplasms 48 Colonic Neoplasms 39 Triple Negative Breast Neoplasms 32 Esophageal Neoplasms 26 Neoplasms 25 Nasopharyngeal Carcinoma 16 Cholangiocarcinoma 16 Biliary Tract Neoplasms 16 Adenocarcinoma 16 Gallbladder Neoplasms 15 Locally Advanced Rectal Cancer 14 Carcinoma, Hepatocellular 13 Brain Neoplasms 10 Adenocarcinoma Of Esophagus 10 Squamous Cell Carcinoma of Head and Neck 9 Esophageal Squamous Cell Carcinoma 9 Bile Duct Neoplasms 9 Head and Neck Neoplasms 8 Gastrointestinal Neoplasms 8 Breast Neoplasms, Male 8 Neuroendocrine Tumors 7 Liver Neoplasms 7 Colorectal Cancer Metastatic 7 Carcinoma, Renal Cell 7 Ovarian Neoplasms 6

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡